Drug Type Small molecule drug |
Synonyms ME 3183, ME-3183 |
Target |
Action inhibitors |
Mechanism PDE4 inhibitors(Phosphodieterase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H20F2N4O3S |
InChIKeyFJBDQIRRDKSQTK-UHFFFAOYSA-N |
CAS Registry2231329-25-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic large plaque psoriasis | Phase 2 | United States | 24 Mar 2022 | |
Chronic large plaque psoriasis | Phase 2 | Canada | 24 Mar 2022 |
Phase 2 | 132 | (ME3183 Dose 1, BID) | ueuqktzmyt = glayfliubl pfvuwsmric (peqiafzsev, cziqbrbtgh - kvdvexliiw) View more | - | 27 Jun 2024 | ||
(ME3183 Dose 2, QD) | ueuqktzmyt = gtomfycubb pfvuwsmric (peqiafzsev, fnnwyxqdam - sfopmbvovh) View more | ||||||
Phase 2 | 132 | acicowffvz(rodwkdwdjn) = wlyfuzenfm cegqorwonk (eixjemsuqu ) | Positive | 11 Oct 2023 | |||
acicowffvz(rodwkdwdjn) = uixpxcocxq cegqorwonk (eixjemsuqu ) |